News Story: Full Text
Sponsored By
AbbVie
Please Click On The Above Banner For More Details
Braintumor Website

 

YM BioSciences closes nimotuzumab trials in North America PBR Staff Writer


Posted on: 05/31/2011

YM BioSciences closes nimotuzumab trials in North America

PBR Staff WriterPublished 31 May 2011

 

YM BioSciences, a drug development company, has decided to terminate two randomized, Phase II, double-blind trials of nimotuzumab in North America due to slow rates of patient accrual and the projected timelines and costs anticipated to complete the studies.

 

Nimotuzumab, a humanized monoclonal antibody targeting EGFR, is indicated for the patients with brain metastasis from non-small cell lung cancer (NSCLC) and palliative treatment of NSCLC.

YM BioSciences said the clinical impression of nimotuzumab continues to reflect favorably upon the drug's safety and efficacy profile.

Once subjects have transitioned from these studies they will be eligible to continue receiving nimotuzumab through an ongoing Special Access Program (SAP) available in Canada.

The company's Phase II, second-line, single-arm study in children with progressive diffuse intrinsic pontine glioma (DIPG) has concluded recruitment at multiple sites in the US, Canada, and Israel.

The company anticipates reporting results in calendar Q3 2011.

YM BioSciences said it will continue to work to secure a license from the US Department of the Treasury's Office of Foreign Assets Control (OFAC) to commercialize nimotuzumab in the US.

Additionally, the company has concluded the scale-up and process development activities in connection with the manufacturing of nimotuzumab.

YM BioSciences expects to produce nimotuzumab in its newly started cGMP manufacturing facility in Havana, Cuba.

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740